Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

13.68USD
11:19am EDT
Change (% chg)

$1.05 (+8.32%)
Prev Close
$12.62
Open
$12.70
Day's High
$13.73
Day's Low
$12.65
Volume
54,509
Avg. Vol
196,661
52-wk High
$22.70
52-wk Low
$10.50

Chart for

About

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $605.28
Shares Outstanding(Mil.): 47.94
Dividend: --
Yield (%): --

Financials

  ABEO.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.74 -- --
ROI: -26.81 1.50 12.72
ROE: -27.17 0.19 14.85

BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial

* ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING

May 18 2018

BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

May 11 2018

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

Apr 23 2018

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

Apr 20 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

Apr 02 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

Apr 02 2018

Earnings vs. Estimates